Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The methylation status of RASSF1A promoter predicts responsiveness to chemotherapy and eventual cure in hepatoblastoma patients.

International journal of cancer - 1 Sept 2008

Honda Shohei, Haruta Masayuki, Sugawara Waka, Sasaki Fumiaki, Ohira Miki, Matsunaga Tadashi, Yamaoka Hiroaki, Horie Hiroshi, Ohnuma Naomi, Nakagawara Akira, Hiyama Eiso, Todo Satoru, Kaneko Yasuhiko

Abstract excerpt

Despite the progress of therapy, outcomes of advanced hepatoblastoma patients who are refractory to standard preoperative chemotherapy remain unsatisfactory. To improve the mortality rate, novel prognostic markers are needed for better therapy planning. We examined the methylation status of 13 ca...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to beta Catenin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Caspase 8

Share to Hepatoblastoma

Share to Multivariate Analysis

Share to Neoadjuvant Therapy

Share to Suppressor of Cytokine Signaling 1 Protein

Share to Suppressor of Cytokine Signaling Proteins

Source

Identifiers

PMID: 18537155
DOI: 10.1002/ijc.23613

Genes

CTNNB1
CASP8
SOCS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18537155-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The methylation status of RASSF1A promoter predicts responsiveness to chemotherapy and eventual cure in hepatoblastoma patients.PMID 18537155Read ↗

Promoter hypermethylation of the RASSF1A gene predicts the poor outcome of patients with hepatoblastoma.Semantic proximity Read ↗

RASSF1A methylation indicates a poor prognosis in hepatoblastoma patients.Semantic proximity Read ↗

RASSF1A and SOCS1 genes methylation status as a noninvasive marker for hepatocellular carcinomaSemantic proximity Read ↗

DNA methylation markers and serum α-fetoprotein level are prognostic factors in hepatocellular carcinomaSemantic proximity Read ↗

Hypermethylation of suppressor of cytokine signaling 1 in hepatocellular carcinoma patients.Semantic proximity Read ↗

Role of RASSF1A promoter methylation in the pathogenesis of hepatocellular carcinoma: a meta-analysis of 21 cohort studies.Semantic proximity Read ↗

RASSF1A promoter hypermethylation is a strong biomarker of poor survival in patients with salivary adenoid cystic carcinoma in a Chinese population.Semantic proximity Read ↗

The tumor suppressor RASSF1A in human carcinogenesis: an update.Semantic proximity Read ↗

Predicting Hepatocellular Carcinoma by Detection of Aberrant Promoter Methylation in Serum DNASemantic proximity Read ↗

Hypermethylation associated with inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human hepatoblastomasSemantic proximity Read ↗

RASSF1A and DOK1 Promoter Methylation Levels in Hepatocellular Carcinoma, Cirrhotic and Non-Cirrhotic Liver, and Correlation with Liver Cancer in Brazilian PatientsSemantic proximity Read ↗

Diagnostic Value of the Methylation of Multiple Gene Promoters in Serum in Hepatitis B Virus-Related Hepatocellular CarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.